Safety and Efficacy of Talactoferrin in Addition to Standard Chemotherapy in Patients With Non-small Cell Lung Cancer
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
No overall officials are registered on this study record. Site-level investigators, where published, appear with their sites below. Why? →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- City of Hope
Duarte, California, United States
Karen ReckampRecruiting - Rush University Medical Center
Chicago, Illinois, United States
Withdrawn - Montefiore Medical Center
The Bronx, New York, United States
Missak HaigentzRecruiting - Duke University Medical Center
Durham, North Carolina, United States
Jeffrey CrawfordRecruiting - Chattanooga Oncology and Hematology Associates
Chattanooga, Tennessee, United States
Davey DanielRecruiting - Sarah Cannon Research Institute
Nashville, Tennessee, United States
David SpigelRecruiting
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 28 Feb 2009
- Primary completion
- 30 Jun 2015
- Completion
- 31 Mar 2016
- Last update posted
- 15 Mar 2012
- Registered enrollment
- 1,100
- Registry id
- NCT00706862
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.